Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells

Vaccine

Volumn 29, Issue 8, 2011, Pages 1634-1642

  Goulart, Cibelly ^a,b   Darrieux, Michelle ^c   Rodriguez, Dunia ^a   Pimenta, Fabiana C ^d   Brandileone, Maria Cristina C ^e   de Andrade, Ana Lucia S S ^f   Leite, Luciana C C ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSIDADE SÃO FRANCISCO   (Brazil)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e INSTITUTO ADOLFO LUTZ   (Brazil)

^f FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Complement; Opsonophagocytosis; PspA; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCAL SURFACE PROTEIN A VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIUM ISOLATE; CLADISTICS; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; FEMALE; IMMUNE RESPONSE; IMMUNOBLOTTING; MOUSE; NONHUMAN; OPSONOPHAGOCYTOSIS; PERITONEUM CELL; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 79952697524     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.074     Document Type: Article

References (32)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374(September (9693)):893-902.
2. Pneumococcal conjugate vaccine for childhood immunization -WHO position paper. Wkly Epidemiol Rec 2007;82(March (12)):93-104.
3. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004;22(June (17-18)):2209-20.
4. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006 Sep;25(9):779-81.
5. Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004;39(October (7)):930-8.
6. Brandileone MC, de Andrade AL, Di Fabio JL, Guerra ML, Austrian R. Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. J Infect Dis 2003;187(April (8)):1206-12.
7. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to Non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the Era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196(November (9)):1346-54.
8. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children -Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59(March (9)):258-61.
9. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009;28(April (4 Suppl.)):S66-76.
10. Yother J, Handsome GL, Briles DE. Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol 1992;174(January (2)):610-8.
11. Ren B, Szalai AJ, Hollingshead SK, Briles DE. Effects of PspA and antibodies to Psp Aonactivation and deposition ofcomplementonthe pneumococcal surface. Infect Immun 2004;72(January (1)):114-22.
12. Hollingshead SK, Becker R, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000;68(October (10)):5889-900.
13. McDaniel LS, Ralph BA, McDaniel DO, Briles DE. Localization of protectioneliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 1994;17(November (50)):323-37.
14. Baril L, Briles DE, Crozier P, King J, Punar M, Hollingshead SK, et al. Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease. Vaccine 2004;23(December (6)):789-93.
15. Hollingshead SK, Baril L, Ferro S, King J, Coan P, Briles DE. Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. JMed Microbiol 2006;55(February (Pt 2)):215-21.
16. Pimenta FC, Ribeiro-Dias F, Brandileone MC, Miyaji EN, Leite LC, Sgambatti de Andrade AL. Genetic diversity of PspA typesamongnasopharyngeal isolates collected during an ongoing surveillance study of children in Brazil. J Clin Microbiol 2006;44(August (8)):2838-43.
17. Brandileone MC, Andrade AL, Teles EM, Zanella RC, Yara TI, Di Fabio JL, et al. Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines. Vaccine 2004;22(September (29-30)):3890-6.
18. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006;32(3):139-53.
19. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000;18(March (17)):1743-54.
20. Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000 Dec;182(6):1694-701.
21. Darrieux M, Moreno AT, Ferreira DM, Pimenta FC, de Andrade AL, Lopes AP, et al. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol 2008;57(March (Pt 3)):273-8.
22. Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, Leite LC, et al. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 2010;17(March (3)): 439-46.
23. Jodar L, Butler J, Carlone G, Dagan R, Goldblatt D, Kayhty H, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003;21(July (23)):3265-72.
24. Ramos CR, Abreu PA, Nascimento AL, Ho PL. A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Braz JMed Biol Res 2004;37(August (8)):1103-9.
25. Briles DE, King JD, Gray MA, McDaniel LS, Swiatlo E, Benton KA. PspA, aprotection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine 1996;14(June (9)):858-67.
26. Romero-Steiner S, Libutti D, Keyserling HL, Carlone GM. Streptococcus pneumoniae opsonophagocytosis using differentiated HL-60 cells Center for Disease Control and Prevention and Emory University Atlanta, GA; 1999.
27. Rodrigues D, Cavada BSA-D-O JT, Moreira RA, Russo M. Differences in Macrophagesstimulation and leukocyte Accumulation in response to Intraperitoneal administration of Glucose/Mannose-Binding Plant Lectins. Braz J Med Biol Res 1992;25:823-6.
28. Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, et al. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun 2010;(March).
29. Brown EJ, Hosea SW, Frank MM. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis 1983;5(September-October (Suppl. 4)):S797-805.
30. Xin W,Li Y,Mo H, Roland KL, Curtiss 3rd R. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 2009;77(October (10)):4518-28.
31. Melin M, Jarva H, Siira L, Meri S, Kayhty H, Vakevainen M. Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun 2009;77(February (2)):676-84.
32. Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, Lima FA, et al. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One 2010;5(5):e10863.